Indivior Pharmaceuticals vs Phibro Animal Health
Phibro Animal Health is the larger business, with $1.52bn of revenue in fiscal 2026 against $1.24bn for Indivior Pharmaceuticals (1.2 times as much). Phibro Animal Health grew faster (17.1% against 4.3%). Indivior Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 16.9% against 6.6%.
| Latest fiscal year | Indivior PharmaceuticalsINDV, 2025 | Phibro Animal HealthPAHC, 2026 |
|---|---|---|
| Revenue | $1.24bn | $1.52bn |
| Revenue growth | 4.3% | 17.1% |
| Net income | $210m | $99.7m |
| Operating margin | 21.1% | — |
| Net margin | 16.9% | 6.6% |
| Return on equity | — | 29.7% |
| Free cash flow | −$93.0m | $9.9m |
| Cash | $195m | $61.4m |
| Total debt | $319m | $738m |
| Debt to equity | — | — |
| Dividend per share | — | $0.48 |
| Dividend yield | — | 1.2% |
| Share buybacks | $11.0m | — |
| Employees | 838 | 2,605 |
| Market value | $4.43bn | $1.53bn |
| Price vs our value range | Above our value range | Within our value range |
| Moat score | — | 49 (Moderate) |
| Insider trades, 12 months | 10 buys, 3 sales | 1 buys, 109 sales |